Aardvark Therapeutics
AARD | NASDAQ
$1.26
-$0.07 (-5.26%)
At close: Nov 16, 2026, 4:00 PM ET
$1.21
-$0.05 (-4.22%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-5.26%
(1D)No price chart data available for 1D timeframe.
Rating
23
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #964/1021 (Top 94%)
Key Statistics
Market Data
Market Cap $27.57M
1D Range
1.21 1.48
52W Range
1.08 15.82
Valuation (TTM)
PE -0.38
PB 0.48
EV/EBITDA 0.44
Valuation (NTM)
Forward PE N/A
Forward PEG -0.04
Price Target $2.50
Cash Flow
FCF Yield -233.6%
SBC Adj. FCF Yield -255.1%
SBC Impact -9.2%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y -64.8% |
N/A
FCF 3Y | 5Y -64.1% |
N/A
Returns
ROA -112.3%
ROE -89.3%
ROIC -130.6%
Financial Health
Net Cash
$60.35M
Current Ratio 9.11
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's n...
Sector Healthcare
Industry Biotechnology
Employees 28
IPO Date Feb 13, 2025
Website aardvarktherapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
8
Consensus
Hold
Price Target
$2.00
Upside
+58.73%
Buy (3)
Hold (4)
Sell (1)
Add to Watchlist
Select watchlists to add or remove AARD